Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07094724

High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients

Led by Gili Regev-Yochay MD · Updated on 2025-08-26

37

Participants Needed

1

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will test whether plasma containing high levels of neturalizing antibodies against West Nile virus (WNV) can help people hospitalized with severe West Nile fever recover faster and avoid serious complications. West Nile virus is spread by mosquitoes and can cause mild flu-like symptoms or, in severe cases, brain infections. Currently, there is no specific medication to treat the infection, and doctors primarily provide supportive care. In this study, patients who are sick enough to require hospitalization will receive plasma donated by people who have recovered from West Nile virus and developed high titer neutralizing antibodies against the disease. Researchers will closely monitor these patients to see how quickly their symptoms improve and whether the plasma helps reduce the risk of death or shorten hospital stays. To evaluate how well the plasma works, researchers will compare these patients to others who were infected in the past for West Nile virus but did not receive plasma. The study will also examine whether the plasma is safe to use and whether it causes any side effects. Through this research, scientists hope to determine if antibody-rich plasma could become a helpful treatment option for people with severe West Nile virus infections.

CONDITIONS

Official Title

High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults hospitalized due to West Nile fever confirmed by positive IgM or PCR in blood or cerebrospinal fluid
  • Symptomatic acute illness including fever and/or neurological symptoms such as headache, somnolence, confusion, seizures, personality changes, extrapyramidal signs, or cranial nerve palsies
  • Diagnostic sample collected within 72 hours prior to enrollment
  • Age 60 years or older OR age 18-59 years with documented immunosuppression including hypogammaglobulinemia, recent anti-CD20 treatment, hematologic malignancy, bone marrow or solid organ transplant, AIDS, or severe primary immunodeficiency
Not Eligible

You will not qualify if you...

  • Age under 60 years without significant immunosuppression
  • More than 72 hours elapsed since diagnostic sample collection
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sheba Medical Center

Ramat Gan, Israel

Actively Recruiting

Loading map...

Research Team

G

Gili Regev-Yochay, MD

CONTACT

A

Almog Cohen-Huszti

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here